The mission of the OSUCCC Proteomics Shared Resource (PSR) is to advance the quality of cancer research while increasing productivity of OSUCCC members at reduced costs through providing high quality instrumentation and expert resources. The PSR provides instrumentation, scientific expertise and shared research services needed for the identification of proteins, protein modifications and protein biomarkers. The methods in proteomic analysis supported by the PSR include protein extraction from biopsies or ce cu tures, 2- dimensional protein separation, protein identification by MALDI-TOF and electrospray ionization coupled with liquid chromatography (LC) mass spectrometry and database searching, protein quantification through image analysis of 2D-gels and protein pattern recognition by SELDI-TOF mass spectrometry for serum analyses. The PSR is designed to provide affordable and high quality service in each of these areas, based on a cost-effective charge-back system. Under the leadership of Dr. Ming-Daw Tsai, the PSR facility provides technical expertise for OSUCCC researchers to submit samples for proteomic analysis as well as a collaborative environment for researchers to discuss with the PSR staff on how to solve a research problem using cutting-edge technology so that these researchers can more effectively and efficiently solve problems of chemical and protein biomarker and diagnosis on cancer samp es and research projects. Since 1999, over $3.8 M of institutional support has been invested in the development of the PSR, with almost half of that amount supporting the purchase of state-of-the-part instrumentation. Although relatively new, the PSR has shown an increasing usage by OSUCCC members, now exceeding 30 members representing all 6 of the OSUCCC research programs. At present, OSUCCC member usage of the PSR represents approximately one-third of the total usage of the facility. Based on historical growth as well as planned growth from new recruitment efforts within the OSUCCC and the role proteomics is beginning to play in profiling the cancer cell, it is projected that OSUCCC members will represent more than 50% of the total PSR usage in the new project period. We now request CCSG funding for the PSR that will provide `23% of the total support for this important full Shared Resource over the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-33
Application #
7630238
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
33
Fiscal Year
2008
Total Cost
$173,973
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Orchard, Tonya S; Andridge, Rebecca R; Yee, Lisa D et al. (2018) Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. J Acad Nutr Diet 118:578-588.e1
Reiff, Sean D; Mantel, Rose; Smith, Lisa L et al. (2018) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov 8:1300-1315
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Qian, Maoxiang; Cao, Xueyuan; Devidas, Meenakshi et al. (2018) TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 36:591-599
Myers, Regina M; Hill, Brian T; Shaw, Bronwen E et al. (2018) Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer 124:816-825
Nemeth, Julianna M; Thomson, Tiffany L; Lu, Bo et al. (2018) A social-contextual investigation of smoking among rural women: multi-level factors associated with smoking status and considerations for cessation. Rural Remote Health 18:4338
Mace, Thomas A; Shakya, Reena; Pitarresi, Jason R et al. (2018) IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67:320-332
Massengill, James B; Sample, Klarke M; Pilarski, Robert et al. (2018) Analysis of the exome aggregation consortium (ExAC) database suggests that the BAP1-tumor predisposition syndrome is underreported in cancer patients. Genes Chromosomes Cancer 57:478-481
Buteyn, Nathaniel J; Fatehchand, Kavin; Santhanam, Ramasamy et al. (2018) Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int Immunol 30:375-383
Hamilton, C A; Miller, A; Casablanca, Y et al. (2018) Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol 148:275-280

Showing the most recent 10 out of 2602 publications